多形性胶质母细胞瘤中采用贴壁淋巴细胞因子激活的杀伤细胞（A-LAK）进行过继性免疫治疗。
Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
作者信息
Munari L, Silvani A, Passerini C G, Radrizzani M, Parmiani G, Boiardi A
机构信息
Istituto Nazionale Neurologico C. Besta, Milano, Italy.
出版信息
J Neurosurg Sci. 1990 Jul-Dec;34(3-4):283-8.
PMID:1965907
Abstract
Adherent lymphokine-activated killer (A-LAK) activity has been recently differentiated in recombinant interleukin-2 (rIL-2) activated PBL. A pilot study on A-LAK + rIL-2 injection into the post-surgical cavity of glioblastoma-operated patients is ongoing. Preliminary data support the feasibility of this technique, which may improve the antitumor response of the host.
摘要
黏附性淋巴因子激活的杀伤细胞（A-LAK）活性最近在重组白细胞介素-2（rIL-2）激活的外周血淋巴细胞（PBL）中得以区分。一项关于将A-LAK加rIL-2注入胶质母细胞瘤手术患者术后腔隙的初步研究正在进行中。初步数据支持了该技术的可行性，这可能会改善宿主的抗肿瘤反应。
Zotero 插件